Novo Nordisk Weight Loss Pill Works as Well as Wegovy, Trial Data Shows

Novo Nordisk announced the results of a Phase III clinical trial This week ou Novo Nordisk rsion of its in-demand drug semaglutide.

The once-daily pill not only outperformed a placebo but did as well as the injecta daily orm of the drug.

Participants lost 15% of their body weight on average by the study’s end, compared to 2.4% in the placebo group. Wegovy summaryFeed_highLightText_ 15% lGi">later this year FDAGLP-1 GLP-1 GLP-1 n> 1 eed_highLightText__NxlGi">Eli Lilly’s 2023GLP-1 span class="summaryFeed_highLightText__NxlGi">Europe 2 hLightText__NxlGi" recent years Novo Nordisk Wegovy June 2021 ig the Food and Drug Administration an class=" Novo Nordisk’s Wegovy Text__NxlGi">Wegovy 17.4% a quarter at least 5% Nearly 90% 2.4% OASIS mmaryFeed_hi Monday tText__NxlGi">15.1% 50 Wegovy and Ozempic ryFeed_highLightText__N OASIS >68 weeks 27 Rybelsus i" Rybelsus n> 14 ghtText__NxlGi">more than 650 25 ext__NxlGi">several mont Rybelsus >